Leap Therapeutics(US:LPTX) Benzingaยท2025-10-07 08:55Core Insights - Leap Therapeutics Inc. is currently trading at $0.69, reflecting a 9.15% decline in pre-market trading [1] - The company has announced a private placement led by Winklevoss Capital, raising $58.88 million through the issuance of common shares and warrants [2][5] - Leap is initiating a digital asset treasury strategy with the support of Winklevoss Capital, which will also fund the development of its therapeutic programs [3] Financial Performance - Leap reported a loss of $0.40 per share in Q2, which was worse than the analyst estimate of a $0.29 loss, with zero revenue reported [6] - The company has a market capitalization of $31.86 million and a yearly trading range between $0.22 and $4.79 [6] Stock Performance - Leap's stock has increased by 163.34% over the past six months, despite a significant decline of 73.48% since the beginning of the year [7] - The stock closed at $0.76 on Monday, marking a 43.15% increase for that day [7] Strategic Developments - As part of the private placement agreement, Leap will expand its board of directors to 12 members, with Winklevoss Capital nominating two directors [5] - The private placement is expected to close on Wednesday, pending customary closing conditions [5] Clinical Developments - Leap's therapeutic program, sirexatamab, recently completed a Phase 2 trial in colorectal cancer patients, with results to be presented at the ESMO Congress 2025 [4]